The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy.
OBJECTIVE
The aim of this study was to evaluate the effect of Helicobacter pylori (H. pylori) treatment on remission of idiopathic central serous chorioretinopathy.


METHODS
Twenty-five patients with idiopathic central serous chorioretinopathy (ICSCR) who were infected with H. pylori were treated with an anti-H. pylori treatment; another twenty-five patients with the same clinical presentations served as the control. Baseline examination and follow up visits at 2, 4, 6, 8, 12, and 16 weeks after the onset of treatment included visual acuity testing and subretinal fluid measurement. The difference between mean visual acuity at the end of 16 weeks and the time of subretinal fluid reabsorption was compared between the two groups.


RESULTS
Subretinal fluid reabsorption time was 9.28±3.20 weeks in the treatment group and 11.63±3.18 weeks in the control group, which was statistically significant (p=0.015). After 16 weeks, mean visual acuity improved to 0.003±0.01 (logMAR) in the treatment group and 0.004±0.02 (logMAR) in the control group. This improvement did not represent a statistically significant difference (p=0.97).


CONCLUSIONS
An anti-H. pylori treatment regimen is effective in the treatment of idiopathic central serous chorioretinopathy patients and anti-H. pylori treatment can provoke the faster reabsorption of subretinal fluid.
Department of Ophthalmology, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammad Bagher
MB
Rahbani-Nobar
Alireza
A
Javadzadeh
Leila
L
Ghojazadeh
Mandana
M
Rafeey
Amir
A
Ghorbanihaghjo
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016022:Case-Control Studies; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000378:metabolism*; D006801:Humans; D008297:Male; D012074:Remission Induction; D055213:Retinal Pigment Epithelium / Q000473:pathology; D012307:Risk Factors; D058471:Subretinal Fluid / Q000382:microbiology; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents
Arch Soc Esp Oftalmol. 2008 Mar;83(3):177-82
18311677
J Fr Ophtalmol. 2004 Dec;27(10):1129-33
15687922
Am J Ophthalmol. 2003 Jul;136(1):182-5
12834690
Am J Cardiol. 2003 Sep 1;92(5):515-21
12943869
Ophthalmology. 2004 Feb;111(2):244-9
15019370
Br J Ophthalmol. 2003 Jun;87(6):709-12
12770966
Retina. 2003 Feb;23(1):1-7; quiz 137-8
12652224
Ophthalmology. 2008 Jan;115(1):169-73
18166410
Retina. 2002 Feb;22(1):25-32
11884874
Minerva Med. 2006 Feb;97(1):39-45
16565697
Br J Ophthalmol. 2003 Jun;87(6):704-8
12770965
Helicobacter. 2008 Aug;13(4):274-7
18665936
Br J Ophthalmol. 1993 Nov;77(11):744-6
8280694
Clin Ter. 2001 Nov-Dec;152(6):393-7
11865536
Recenti Prog Med. 2009 Feb;100(2):91-6
19350802
Med Hypotheses. 2004;63(3):524-7
15288381
Ophthalmology. 2002 Oct;109(10):1834-7
12359603
J Fr Ophtalmol. 2002 Dec;25(10):1021-5
12527825
Atherosclerosis. 2009 Feb;202(2):535-42
18599062
Acta Ophthalmol. 2008 Mar;86(2):126-45
17662099
Swiss Med Wkly. 2004 Jul 10;134(27-28):395-8
15389356
Am J Ophthalmol. 2005 Jan;139(1):87-99
15652832
Am J Ophthalmol. 2002 Jun;133(6):787-93
12036670